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INTRODUCTION
Age-related macular degeneration (AMD) is a mul tifactorial disease with an increasing prevalence worldwide and significant morbidity. Initial studies in the early 1980s indicated the significant burden that AMD would have in the following years. A hereditary polygenic component is one of the main risk factors for the development of AMD; however, a variety of other factors are involved in its pathogenesis, including age (major risk factor), ethnicity, genetics, family history, light exposure, vitamin deficiency, high body mass index (BMI), and smoking (1, 2) . Cumulative evidence has indicated Circulating levels of mannose-binding lectin (MBL) in age-related macular degeneration that inflammation plays a fundamental role in the development of AMD, with the complement system playing a central underlying role in the physiopathological process in addition to the vascular endothelial growth factor (VEGF) (3, 4) . Serum levels of both VEGF and complement proteins have been found to be increased in AMD. In addition, the special role of the alternative pathway (AP) of the complement system has been described (5) . Genetic variants of factors H and B, which are responsible for the inhibition and activation of the AP cascade, respectively, have been shown to be associated with AMD (6, 7) . In addition to AP, the classic pathway and lectin pathway (LP) of the complement system appear to be necessary for full complement activation and tissue damage in AMD. Joseph et al. showed that in the retinal pigmented epithelial (RPE) cell monolayer, cell lysis does not occur with only AP components, but requires the additional presence of LP components (8) . LP is initiated by the binding of pattern recognition molecules, such as mannose-binding lectin (MBL), ficolins, and collectins, to carbohydrates or acetylated residues present on the surface of microorganisms (known as pathogen-associated molecular patterns) or on aberrant glycocalyx patterns of apoptotic, necrotic, or malignant cells (4) . MBL is a key protein of LP, which plays a pivotal role in innate immunity and participates in a myriad of biological processes, including carcinogenesis, atherogenesis, and clearance of senescent cells. MBL levels are widely heterogeneous in the general population, and the optimal levels of the protein probably change at different ages, as well as in distinct environmental contexts (9) . MBL may offer protection against invading microorganisms; however, high MBL levels may cause biological disadvantages in other situations through the aggravation of local and systemic inflammation involving complement activation and modulation of proinflammatory cytokine production (10) . In a recent study, diabetic retinopathy was associated with high MBL levels in a Chinese population (11) .
In this study, we investigated the role of MBL in AMD, which is a key element in the activation of LP. In addition, we aimed to determine the association between serum MBL levels and the development and clinical features of AMD.
METHODS
This was a case-controlled study conducted according to the Declaration of Helsinki. All patients submitted a written informed consent and were examined by at least one retinal specialist at the Vision Centre of the Fe deral University of Paraná. The ethics committee of the Clinical Hospital, Federal University of Paraná, in Curitiba, Brazil, approved the study.
Patients and controls
The study included patients with AMD (category 3 non-exudative AMD or late disease and geographic atrophy or exudative AMD) and age-matched controls. Patients and controls were recruited between July 2011 and January 2014, during regularly scheduled ophthalmologic evaluations at the Vision Centre, Department of Ophthalmology, Federal University of Paraná in Curitiba, Brazil. Patients with AMD and controls with the following inclusion criteria were included:
Patients with AMD 1. Age >55 years 2. History of AMD presenting with large confluent soft drusen (>125 μm) in both eyes or one eye with large drusen and the other eye with either geographic atrophy (>360 μm) or choroidal neovascularization 3. No eye disease other than previous cataract with uncomplicated extraction 4. No history of diabetes or uncontrolled systemic arterial hypertension (self-reported use of medication or physician diagnosed) 5. Refractive error (spherical equivalent) ±4.00 diopters Controls All the above criteria, except for item 2. All patients and controls underwent complete ophthalmologic examination (including best-corrected visual acuity using an ETDRS chart) and fundus examination performed by a retinal specialist. Patients who met the study criteria underwent optical coherence tomography (OCT) imaging of both eyes with a specific imaging protocol. Additional fluorescein angiography was performed in some patients with diagnostic doubt (e.g., vascular disease and macular dystrophy).
Imaging protocol
To ensure that the patients and controls had no macular disease, OCT was performed using the protocol of the "University of Wisconsin, School of Medicine and Public Health, Fundus Photograph Reading Center, Non-study Specific Stratus OCT 3)." The following two scan types were performed: fast macular thickness map scan and cross hair scan. All participants underwent a fast macular thickness map scan [centered on the macula, with the retinal boundaries indicated by white lines in the underlying scans (the internal limiting membrane and the retinal pigment epithelium) not containing obvious major errors at the center of the macula] and a 6-mm cross hair scan (centered on the foveal region). A minimal signal strength of 5 was necessary.
Blood samples and MBL serum levels
Venous blood samples were collected from all patients and controls included in the study. The blood samples were allowed to clot and were centrifuged. The obtained serum samples were aliquoted and stored at -80°C until use. Serum MBL levels were measured using a time-resolved immunofluorometric assay (TRIFMA) as described by Frederiksen et al. (10) . In brief, the diluted serum samples were incubated in mannan-coated wells. After washing, the bound MBL was estimated by applying biotinylated anti-MBL, followed (after washing) by europium-labeled streptavidin and time-resolved fluorometry.
Statistical analysis
AMD cases in Curitiba (a city in South Region, Brazil) were estimated using the demographic features of the Brazilian census in 2013. The Kolmogorov-Smirnov and Mann-Whitney tests were used to compare serum MBL levels. Fisher's exact and chi-squared tests were used for single and demographic comparisons (i.e., age, ethnicity, sex, smoking habit, and BMI), respectively. Values <5% were considered significant.
RESULTS
A total of 136 participants were included in this study. The AMD group included 68 participants (63 European descendants and five Afro-descendants; 33 men and 35 women), including 34 with exudative and 34 with nonexudative clinical presentations ( Table 1 ). The control group included 68 participants (63 European descendants and five Afro-descendants; 27 men and 41 women) without identifiable eye disorders. There was no significant difference in age, sex, or BMI between the groups. In the AMD group, 37 (54%) patients had BMI >25 kg/m 2 , and in the control group, 44 (65%) had BMI >25 kg/m 2 . Smoking habits were similar in both groups (Table 1) .
There was no significant difference in serum MBL levels between patients with AMD (median, 608 ng/mL; range, 30-3,415 ng/mL) and controls (median, 739 ng/mL; range, 30-6,039 ng/mL; p=0.1059, Figure 1 ). Serum MBL levels did not differ between patients with exudative AMD (median, 476 ng/mL; range, 30-3,415 ng/mL) and nonexudative AMD (median, 692 ng/mL; range, 30-2,587 ng/mL; p=0.3291, Figure 2 ).
Serum MBL levels were divided into the following categories according to the values: low (<100 ng/mL), intermediate (100-2,000 ng/mL), and high (>2,000 ng/mL). The distribution was similar between patients with AMD 
DISCUSSION
The complement system represents a major mechanism in innate host defenses. The three pathways, classic, alternative, and lectin, which can activate the complement system, need to work simultaneously with fine adjustment to maintain homeostasis. Deregulation in complement system activation may be related to the development or aggravation of several diseases, including AMD (12, 13) . Therefore, a stable and mild MBL level appears to be necessary for a healthy life (9) . There is evidence that systemic inflammation is present in AMD, with elements of the complement system (C3, C4, and factor B) found at higher levels in the blood samples of patients with AMD, indicating an inflammatory state not restricted to the retina (14) .
The incidence and prevalence of AMD are increasing in different populations, including Brazilian, mainly because of factors such as increased life expectancy, sun exposure, smoking, and obesity. Currently, AMD is the leading cause of vision loss in industrialized countries (15, 16) .
Several eye diseases, such as glaucoma, diabetic re tinopathy, and uveitis, appear to be linked to some type of immune deregulation (17) . The activation of the complement cascade by the classical, alternative, or LP, pro duces inflammatory mediators and leads to target cell damage by the membrane attack complex (17) . A low level of complement activation constantly occurs in the eye and is probably needed for protection against pathogens. To regulate and control excessive complement activation that would be damaging to the tissue, ocular fluids and cells express a number of complement regulatory proteins (18) . It has been well-established that complement activation has a role in AMD, particularly regarding AP, which is related to polymorphisms of the human factor H gene (19) (20) (21) . To our knowledge, there is no information on the role of LP in AMD. However, at least in a mouse model, low expression of LP compo nents in retinal tissue was observed and the whole complement system was required for the development of AMD, particularly the exudative form (22, 23) . Additionally, LP is apparently involved in the lysis of RPE cells in vitro (8) .
In the present study, serum MBL levels did not differ either between patients with AMD and controls or between exudative and nonexudative forms of AMD. Similar results were found in a study from Australia (24) . It is im portant to emphasize that this Australian study had the same exclusion criteria, AMD definition and plasma MBL levels. The MBL levels obtained for controls were 739 ng/mL in Brazil and 720 ng/mL in Australia (median); the MBL levels in patients with AMD were 608 ng/mL in Brazil and 740 ng/mL in Australia.
LP is initiated when MBL ficolins (L, H, or M) or collectins bind to the microorganism surface (independently of an antibody). Therefore, LP plays an important role in innate immunity. Moreover, MBL/fi colins promote opsonization and phagocytosis of target pathogens. After pathogen binding by MBL/ficolins, MBL-associated serine proteinases (MASP-1 and -2) are activated, followed by complement activation. Structural mutations in the MBL gene may lead to low levels (deficiency) of the protein, thereby increasing susceptibility to infections, particularly at an early age. Conversely, high levels of MBL may be related to inflammatory di seases. For example, patients with retinal herpes infection and endophthalmitis present with high MBL levels (25) . Chow et al. evaluated blood and ocular samples (aqueous and/or vitreous) in patients with endophthalmitis and showed that MBL was significantly elevated in inflamed human eyes, but was virtually undetectable in noninflamed eyes, suggesting that MBL has a role in sight-threatening ocular inflammation (25, 26) .
It is reasonable to consider that a similar immunological environment occurs in AMD, with activation of all complement pathways (27, 28) . The levels of the components of all pathways of the complement system can increase (in the blood and eyes). However, the relatively high molecular weights of C1q and MBL could be an obstacle for their introduction into retinal circulation. C1q weighs approximately 460 kDa and MBL weighs MBL= mannose-binding lectin; AMD= age-related macular degeneration. Figure 2 . Serum MBL levels (ng/mL) in patients with exudative and nonexudative AMD. 450 kDa, whereas factor H weighs only 150 kDa (29) . This may explain why no classic or LP molecules were found in drusen (30) . A study including intravitreal samples and MBL measures would be able to clarify this point, but such a study would involve invasive examinations, with risks and ethical issues. In diabetic retinopathy, there is a trend toward high MBL levels in the retina and vitreous (11) . Vascular abnormalities with a break in the hematorretinian barrier may explain this finding. However, more studies will be necessary for further clarification.
In conclusion, serum MBL levels did not significantly differ between patients with AMD and controls or between exudative and nonexudative forms of AMD. These results suggest that MBL does not play a major role in the development of AMD or in its clinical presentation.
